secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-046254
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma reports Q3 net loss $44.6M; cash $460.7M funds into 2027
---------------------------------------------------------------------------

- Net loss of $44.6M for Q3 2024, improved from $50.9M in Q3 2023; non-GAAP net loss $37.1M.
- Cash, cash equivalents and marketable securities $460.7M as of Sept 30, 2024; provides runway into 2027.
- Completed ImmPACT Bio acquisition; added IMPT-314, a CD19/CD20 CAR T candidate with Phase 1 data at ASH 2024.
- Expect to initiate pivotal trial for IMPT-314 in 2025 in relapsed/refractory LBCL; initial Phase 1 data at ASH Dec 9.
- Phase 1 trial of LYL119 for ROR1-positive solid tumors ongoing; initial clinical data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024046254/0001628280-24-046254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024046254/lyel-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer